TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent
Phase 1TerminatedDevelopment Stage
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Jan 7, 2022 → Sep 17, 2022
About TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent
TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent is a phase 1 stage product being developed by Tonix Pharmaceuticals for Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2. The current trial status is terminated. This product is registered under clinical trial identifier NCT05216510. Target conditions include Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05216510 | Phase 1 | Terminated |
Competing Products
2 competing products in Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tapentadol IR + Oxycodone IR | Johnson & Johnson | Pre-clinical | 23 |
| ECMPS-IEM | Novartis | Phase 2 | 52 |